Collectively, these findings indicate that targeting CD39/CD73/A2A/A2B represents a promising strategy to overcome immune-exclusion in CCA and convert immunologically “cold” tumors into “hot,” treatment-responsive states (84). This evidence concerns the gene NT5E and cholangiocarcinoma.